Skip to content
Review Open access

PROGRESS: Implementing a hybrid decentralized clinical trial to advance precision oncology and improve cancer care quality and equity across North Carolina oncology practices.

Oct 2026 · JCO Oncology Practice · Vol 22, pp. 70-70 · 0 citations

TL;DR

The implementation of PROGRESS using hDCT methodology generated practical insights to strengthen partnerships with CPLs and identify scalable approaches to improve cancer care quality via precision medicine support and local clinical research opportunities.

Abstract

70 Background: Rates of comprehensive molecular profiling (CMP), use of evidence-based genome-informed therapy (GIT), and clinical trial participation remain low despite being markers of high-quality cancer care. PROGRESS is an interventional study evaluating the impact of a centralized precision oncology navigator and pharmacist-led expert CMP review on GIT ordering and cancer outcomes across an academic medical center (AMC) and community practice locations (CPLs) in North Carolina. Using hybrid decentralized clinical trial (hDCT) methods, the study was designed to increase access while minimizing clinician burden. We describe key operational challenges and solutions. Methods: PROGRESS was operationalized as an hDCT in which CPL providers were not considered research-engaged because all assessments performed locally were standard of care. Regulatory oversight remained at the AMC. Pre-launch meetings assessed CPL interest and workflow integration. AMC-led launch meetings included CPL providers, investigators, study coordinators (SC), and regulatory staff. An AMC-based SC identified potential subjects via the shared electronic health record (EHR), obtained remote electronic consent, and coordinated expert CMP reviews documented in the EHR. Follow up data were collected via medical record abstraction. Descriptive qualitative and process-level metrics were used to identify barriers and guide workflow adaptations. Results: In addition to the AMC, 3 CPLs approached were onboarded with n = 100 subjects enrolled over 11 months. Key facilitators included: a local study champion, integrating into existing workflows, and addressing remote consent concerns. Post-launch enrollment barriers included: heterogeneous CMP vendor use, limited multidisciplinary support, participant language and health-literacy challenges, subject research-fatigue, and inefficient prescreening tools. Implementation challenges highlighted opportunities to standardize biomarker testing pathways, provide CMP financial assistance counseling, and monitor demographics to support equitable participation. Post-implementation adaptations included monthly newsletters, a protocol amendment accommodating CMP ordering workflows, removal of burdensome surveys, translated consent forms, and an EHR-based prescreening report minimizing clinician involvement. Following these changes, enrollment increased by 116.1% in the second 6 months versus the first six months. Accrual is ongoing and primary study endpoint results will be reported separately. Conclusions: The implementation of PROGRESS using hDCT methodology generated practical insights to strengthen partnerships with CPLs and identify scalable approaches to improve cancer care quality via precision medicine support and local clinical research opportunities. Clinical trial information: NCT06896162 .

Read PDF

Similar papers

Review Open access Oct 2026

Results from a multisite quality improvement initiative in solid tumor precision medicine.

582 Background: Timely, comprehensive biomarker testing is essential to identify actionable genomic alterations and guide targeted therapy in patients with advanced solid tumors. However, community and academic cancer centers often encounter delays in ordering, prolonged turnaround from diagnosis to results, an...

Amany R. Keruakous, W. Waugh, Samuel K. Caughron et al. · 0 citations
Review Open access Oct 2026

Improving clinical trial enrollment rates among patients with operable invasive breast cancers: An ASCO Quality Training Program initiative.

610 Background: Clinical trial participation is essential for advancing cancer care and recommended in National Comprehensive Cancer Network guidelines. At Kaiser Permanente San Francisco (KPSF), 5% of patients with early-stage breast cancer enrolled in a clinical trial in 2024, similar to community standards....

M. Yang, Jenny Wei, Quyen Chau et al. · 0 citations
Review Open access Oct 2026

Precision oncology at speed: workflow design determines clinical utility in rapid molecular testing for lung cancer

Abstract Purpose Matching patients with effective targeted therapies requires timely molecular results; however, the challenge today how to embed it into routine clinical workflows in ways that meaningfully affect patient-level treatment decisions. Methods Building on prior work, the authors systematically reviewed lab...

B. Sheffield, Katherina Baranova, P. Cheema et al. · 0 citations
Open access Oct 2026

ASCO QTP project to improve equity in cancer clinical trials.

578 Background: Clinical trials are a core component of high-quality cancer care, yet minority enrollment in oncology treatment trials at the University of Wisconsin Carbone Cancer Center (UWCCC) was 5.8% in 2023, which is lower than the Wisconsin cancer catchment rate of 9.6%. Methods: As part of the ASCO’s...

M. Patel, A. Bradley, Meredith Winkelhake et al. · 0 citations
Review Open access Oct 2026

Molecular tumor boards implementation in Europe: a scoping review and thematic analysis of challenges and facilitators.

BACKGROUND Molecular Tumor Boards (MTBs) are increasingly recognized as key instruments for integrating genomic data into clinical decision-making in precision oncology. While evidence suggests that MTBs may improve patient outcomes, their implementation across European healthcare systems remains heterogeneous. This sc...

N. Lentini, E. Giacobini, Luigi Russo et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.